σ1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 5, 2010, Pages

  Tagashira, Hideaki ^a   Bhuiyan, Shenuarin ^a   Shioda, Norifumi ^a   Hasegawa, Hideyuki ^a   Kanai, Hiroshi ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Akt; Endothelial nitric oxide synthase; Protein kinase B

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUVOXAMINE MALEATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PAROXETINE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; SIGMA 1 OPIATE RECEPTOR; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ARCH; AORTA CONSTRICTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL MODEL; AORTA; CELL CULTURE; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RAT; TIME; VASOCONSTRICTION; WISTAR RAT;

ANIMALS; AORTA; CELLS, CULTURED; FLUVOXAMINE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED ICR; MODELS, ANIMAL; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE III; PAROXETINE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; VASOCONSTRICTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 78249246381     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00198.2010     Document Type: Article

References (52)

1. Atar D, Malinin A, Takserman A, Pokov A, van Zyl L, Tanguay JF, Lesperance F, Serebruany V. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans. J Clin Psychopharmacol 26: 172-177, 2006.
2. Bhuiyan MS, Fukunaga K. Stimulation of sigma-1 receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats. Expert Opin Ther Targets 13: 1253-1265, 2009.
3. Bhuiyan MS, Fukunaga K. Stimulation of sigma-1 receptor by dehydroepiandrosterone ameliorates hypertension-induced kidney hypertrophy in ovariectomized rats. Exp Biol Med 235: 356-364, 2010.
4. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab 293: E1606-E1614, 2007.
5. Bhuiyan MS, Tagashira H, Fukunaga K. Dehydroepiandrosterone mediated stimulation of sigma-1 receptor activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding (Abstract). Cardiovasc Ther; http://www.ncbi.nlm.nih.gov/pubmed/20553277.
6. Bhuiyan MS, Shioda N, Shibuya M, Iwabuchi Y, Fukunaga K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 53: 57-63, 2009.
7. Carrithers M, Tandon S, Canosa S, Michaud M, Graesser D, Madri JA. Enhanced susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice. Am J Pathol 166: 185-196, 2005.
8. Charalampopoulos I, Tsatsanis C, Dermitzaki E, Alexaki VI, Castanas E, Margioris AN, Gravanis A. Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acad Sci USA 101: 8209-8214, 2004.
9. Cooper GL. The safety of fluoxetine: an update. Br J Psychiatry 153: 77-86, 1988.
10. Dumont M, Lemaire S. Interaction of 1,3-di(2-[5-3H]tolyl) guanidine with sigma 2 binding sites in rat heart membrane preparations. Eur J Pharmacol 209: 245-248, 1991.
11. ++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 269: 1300-1309, 1994.
12. Ela C, Hasin Y, Eilam Y. Apparent desensitization of a sigma receptor sub-population in neonatal rat cardiac myocytes by pre-treatment with sigma receptor ligands. Eur J Pharmacol 295: 275-280, 1996.
13. Fialova K, Krizanova O, Jarkovsky J, Novakova M. Apparent desensitization of the effects of sigma receptor ligand haloperidol in isolated rat and guinea pig hearts after chronic treatment. Can J Physiol Pharmacol 87: 1019-1027, 2009.
14. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 46, Suppl 2: 42-44, 1985.
15. Fuchs E, Czeh B, Flugge G. Examining novel concepts of the pathophysiology of depression in the chronic psychosocial stress paradigm in tree shrews. Behav Pharmacol 15: 315-325, 2004.
16. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 299: 818-824, 2001.
17. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288: 701-709, 2002.
18. Golding M, Kotlyar M, Carson SW, Hoyler S, Lazarus C, Davidson C, Guzzo J, Sontz E, Garbutt JC. Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses. Psychopharmacology 182: 321-326, 2005.
19. Golding M, Kotlyar M, Garbutt JC, Guzzo J, Sontz E, Hinderliter A, Carson SW. Paroxetine modulates psychological and sympathetic responses during public speaking. J Clin Psychopharmacol 22: 98-99, 2002.
20. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 9: 197-204, 2009.
21. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3K-Akt pathway in human endothelial cells. Circ Res 87: 677-682, 2000.
22. 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 268: 9-18, 1994.
23. 1 receptor binding but does not affect its mRNA levels in the guinea pig or rat brain. Eur J Pharmacol 401: 307-316, 2000.
24. 11C]SA4503. Biol Psychiatry 62: 878-883, 2007.
25. Lu YM, Shioda N, Han F, Moriguchi S, Kasahara J, Shirasaki Y, Qin ZH, Fukunaga K. Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes. Biochem Pharmacol 74: 1727-1737, 2007.
26. Manning WJ, Wei JY, Katz SE, Litwin SE, Douglas PS. In vivo assessment of LV mass in mice using high-frequency cardiac ultrasound: necropsy validation. Am J Physiol Heart Circ Physiol 266: H1672-H1675, 1994.
27. 1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav 84: 581-597, 2006.
28. + channels in the heart. J Pharmacol Exp Ther 322: 341-350, 2007.
29. 473-phosphorylation of Akt-1 in PC12 cells. Life Sci 86: 309-314, 2010.
30. Narita N, Hashimoto K, Tomitaka S, Minoabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307: 117-119, 1996.
31. Novakova M, Bruderova V, Sulova Z, Kopacek J, Lacinova L, Kvetnansky R, Vasku A, Kaplan P, Krizanova O, Jurkovicova D. Modulation of expression of the sigma receptors in the heart of rat and mouse in normal and pathological conditions. Gen Physiol Biophys 26: 110-117, 2007.
32. Novakova M, Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol 286: 19-30, 1995.
33. Novakova M, Ela C, Bowen WD, Hasin Y, Eilam Y. Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Eur J Pharmacol 353: 315-327, 1998.
34. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 20: 137-140, 2000.
35. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 88: 8277-8281, 1991.
36. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation 111: 250-253, 2005.
37. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 104: 1894-1898, 2001.
38. 3H]3-PPP binding to sigma sites in rat brain. Eur J Pharmacol 165: 335-336, 1989.
39. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, O'Connor CM; Sertraline Antidepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108: 939-944, 2003.
40. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 43: 453-462, 2001.
41. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 119: 113-116, 2006.
42. Shirayama Y, Nishikawa T, Umino A, Takahashi K. p- Chlophenylalaninereversible reduction of σ binding sites by chronic imipramine treatment in rat brain. Eur J Pharmacol 237: 117-126, 1993.
43. Shores MM, Pascualy M, Lewis NL, Flatness D, Veith RC. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 26: 433-439, 2001.
44. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 144: 3449-3455, 2003.
45. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 64: 4875-4886, 2004.
46. Swenson JR, O'Connor CM, Barton D, Van Zyl LT, Swedberg K, Forman LM, Gaffney M, Glassman AH; Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 92: 1271-1276, 2003.
47. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS; ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62: 792-798, 2005.
48. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-α levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 170: 429-433, 2003.
49. Wang L, Duncan G. Silencing of sigma-1 receptor induces cell death in human lens cells. Exp Cell Res 312: 1439-1446, 2006.
50. Yamaguchi O, Higuchi Y, Hirotani S, Kashiwase K, Nakayama H, Hikoso S, Takeda T, Watanabe T, Asahi M, Taniike M, Matsumura Y, Tsujimoto I, Hongo K, Kusakari Y, Kurihara S, Nishida K, Ichijo H, Hori M, Otsu K. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci USA 100: 15883-15888, 2003.
51. 1 receptor mRNA in rat brain by a putative atypical antipsychotic and sigma receptor ligand. Neurosci Lett 282: 169-172, 2000.
52. Zeng G, Nystrom Fh Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539-1545, 2000.